Search

Renown Health is pleased to announce that Susan Lee, DO, MBA will serve as Chief Operating Officer for Renown South Meadows Medical Center. Dr. Lee begins her new role on March 7, and succeeds Chris Nicholas, who resigned last month for a position with a health system in Florida. Tony Slonim, MD, DrPH, President & CEO, Renown Health, announced Dr. Lee’s internal promotion today by writing, “Embracing our vision to improve the health of our community, we are empowering leaders to play a greater role in improving physician, employee and patient experiences; growing services to our community; providing Reliable and Exact Care and meeting rigorous standards for operational excellence and efficiency.” Dr. Slonim noted that he was excited as, “Dr. Lee expands her role, promotes a spirit of unity across the enterprise, and continues to make progress on achieving goals central to Renown’s success.” In her new role as Chief Operating Officer for Renown South Meadows Medical Center, Dr. Lee will work with Jennifer Allen, MSN, director of nursing and the South Meadows leadership medical staff and team to lead South Meadows to achieve its strategic and operational goals. Dr. Lee is an experienced, dynamic physician executive and operational leader with a record of service growth, clinical quality, patient communication and execution. She is experienced in cross-functional collaboration and nationally recognized for organizational change management. Board certified in Internal Medicine and Psychiatry, Dr. Lee has based her clinical practice as a hospitalist on the mind-body connection and a collaborative model with patients and families. Dr. Lee joined Renown Health as the Chair of Medical Specialties in the summer of 2020 to manage hospital-based physician practices. She was promoted to Chief Medical Officer for Renown Regional Medical Center in February 2021 to oversee inpatient clinical operations, including length of stay, hospital capacity, care management functionality, interdisciplinary rounds and Medical Staff services. Since September of 2021, as Chief Medical Officer for Renown Acute Care, she has been responsible for clinical operations, strategic direction, hospital-based physician management, the Medical Staff Office, regulatory standards, and quality and financial outcomes for Renown Regional Medical Center, Renown South Meadows Medical Center and Renown Rehabilitation Hospital. Prior to serving at Renown, Dr. Lee served as Chief of Hospital Medicine at Carilion Clinic, a 7-facility nonprofit, integrated health system headquartered in Roanoke, Virginia. Dr. Lee is a graduate of the University of Massachusetts Amherst (MBA), Nova Southeastern University College of Osteopathic Medicine (DO) and Duke University (BA). She is an active member of the American College of Healthcare Executives and the American Association for Physician Leadership. Renown South Meadows Medical Center, located in south Reno, is a 76-bed acute care community hospital offering exceptional surgical and medical services in a nurturing environment. Renown South Meadows Medical Center is home to south Reno’s only 24/7 Emergency Department and staffed with Board-Certified Emergency physicians. Renown South Meadows Medical Center offers advanced care for patients including comprehensive primary care; x-ray and imaging services; lab services; heart care; OB/GYN; physical rehabilitation and pulmonary rehabilitation services; nuclear medicine and surgical services including orthopedics. As a not-for-profit organization, the Renown South Meadows Medical Center team embraces their role in improving the health and well-being of the people and communities served and provides necessary healthcare services regardless of race, creed, sex, national origin, handicap, age or ability to pay. In addition, Renown South Meadows Medical Center has been nationally recognized for providing the highest quality care and service, including: In U.S. News and World Report Best Hospital rankings, Renown South Meadows was listed #1 in the State of Nevada (tied with Carson Tahoe Medical Center) for 2020. Renown South Meadows was rated High Performing for Hip Replacement and Knee Replacement and COPD. A hospital's score is based on multiple data categories, including patient outcomes, safety and volumes. Hospitals earning a High Performing rating were significantly better than the national average. Renown South Meadows Medical Center received The Joint Commission’s Gold Seal of Approval® accreditation for Total Knee Replacement, Total Hip Replacement and Total Shoulder Replacement and was recognized as Top Performer on Key Quality Measures.® Dr. Lee says she "understands that health care today is as much about social skills and navigating multiple relationships as it is about clinical knowledge." Throughout her career, Dr. Lee has done much to contribute to a culture of innovation and transformation. Dr. Lee believes that, “providers need physicians, nurses and care teams who have high adaptability, flexibility, and, above all, the ability to care and be kind." Dr. Lee coaches teams to be responsive, empathic, have situational awareness and employ their clinical abilities at the highest level. She will often ask questions of her team to understand how they are "wired" to drive innovation and transformation- and to build culture and teamwork. She has hired and coached over 100 hospitalist physicians — many of them women — and promoted and served as a reference for hundreds of nurses, staff leader and advanced care providers. Dr. Lee serves as a peer mentor for other women, and men, who aspire to physician and healthcare leadership. The team at Renown South Meadows Medical Center is seeking great employees for careers in service; apply on line at https://careers.renown.org/.

Read More About Dr. Susan Lee to Lead Renown South Meadows Medical Center

Gilead Sciences, Inc. (Nasdaq: GILD) and the Renown Institute for Health Innovation (IHI) today announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of nonalcoholic steatohepatitis (NASH) and potentially inform development of treatment options for the disease. Under the terms of the collaboration and license agreement, Gilead will provide funding to Renown IHI to sequence and analyze the DNA of 15,000 individuals living with NASH or nonalcoholic fatty liver disease (NAFLD) as well as a control cohort of 40,000 individuals in Nevada. “Combining the sequencing of protein coding DNA, with extensive electronic health record data will enable a deep analysis of the roles of genetics and environment in NASH incidence and progression,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “The analysis of these large datasets in collaboration with Renown IHI could help identify genetic variants that impact the risk of developing NASH and thereby advance the discovery and development of new treatments for this disease.” Renown Health is Nevada’s most comprehensive and integrated healthcare network and maintains electronic health records for 1.02 million registered patients. In 2016, Renown Health and the Desert Research Institute established the Healthy Nevada Project (HNP), the nation’s first community-based population health study. In 2017 HNP began a partnership with Helix to leverage its population health services, Exome+™ sequencing, and consumer engagement tools. The HNP is now an ongoing collaboration between Renown IHI, the Desert Research Institute, a global leader in environmental data and applied research, and Helix, a personal genomics company. HNP combines genetic, environmental, social and clinical data to address individual and community health needs with the goal of improving health across the state and the nation. The HNP currently has 40,000 participants. “Combining genetic sequencing with large sets of data can play a critical role in understanding and identifying serious health risks, including diseases like NASH. We are excited to collaborate with Gilead to better understand the condition and its complexities,” said Anthony Slonim, MD., DrPH. “Any genetic variants identified in participants through the collaboration may be shared with the participants for patient care purposes.”     About NASH Nonalcoholic steatohepatitis (NASH) is a chronic form of liver disease characterized by excess fat in the liver, inflammation, and liver cell damage. Inflammation and liver cell damage can cause scarring of the liver, or fibrosis, and ultimately lead to cirrhosis or liver cancer. NASH is more common in people with certain conditions, including obesity and type 2 diabetes. There are currently limited approved treatments for patients living with NASH.   About Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.   About Renown Health Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Renown is one of the region’s largest private employers with a workforce of more than 7,000. It comprises three acute care hospitals, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown Health’s commitment has extended beyond traditional health care to include community health and well-being. Renown Health works to improve health care through science, research and genetics; forge community partnerships that improve lives and develop innovative models that are improving health care in Nevada. For more information, visit renown.org.    About Helix Helix’s mission is to empower every person to improve their life through DNA. Helix is accelerating the integration of genomic data into clinical care and broadening the impact of large-scale population health programs by providing comprehensive expertise in DNA sequencing, bioinformatics, and individual engagement. Powered by their proprietary Exome+™ assay—a panel-grade exome enhanced by more than 300,000 informative non-coding regions—Helix offers health systems a scalable solution which enables the discovery of medically relevant, potentially life-saving, genetic information. Additionally, Helix offers a suite of DNA-powered products for continued individual engagement and discovery. Helix is headquartered in the San Francisco Bay Area and has one of the world’s largest CLIA-certified, CAP-accredited Next Generation Sequencing labs, located in San Diego, California. Learn more at www.helix.com. Helix, the Helix logo, and Exome+ are trademarks of Helix Opco, LLC.   Gilead Forward-Looking Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential benefits of this collaboration, and Gilead may fail to discover, develop and commercialize any product candidates for the treatment of NASH. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.   Additional Media Contact: Sung Lee, Investors                                                                                                                                                        650-524-7792 Arran Attridge, Media                                                                                                                                                        650-425-8975

Read More About Gilead Sciences and Renown Institute for Health Innovation Announce Strategic Collaboration to Advance Understanding of Nonalcoholic Steatohepatitis (NASH)

Healthy Nevada Project’s community-based approach reveals up to 90% of CDC Tier 1 genetic condition risks missed using clinical care guidelines. In a new study published today in the journal Nature Medicine, researchers behind the Healthy Nevada Project® suggest that community-based genetic screening has the potential to efficiently identify individuals who may be at increased risk for three common inherited genetic conditions known to cause several forms of cancer and increased risk for heart disease or stroke. In 2018, the Healthy Nevada Project® (the largest, community-based population health study combining genetic, clinical, environmental and social data) started notifying consenting study participants who have certain genetic variants which predispose them to the Centers for Disease Control and Prevention (CDC) Tier 1 genetic conditions. The study focused on identifying carriers of these conditions, which include Hereditary Breast and Ovarian Cancer, Lynch Syndrome, and Familial Hypercholesterolemia, because they are the most common conditions and early detection and treatment could significantly lower morbidity and mortality. Initial results from almost 27,000 study participants showed that 90% of carriers of the CDC Tier 1 genetic conditions were not previously identified in a clinical setting. The authors conclude that population genetic screening would identify at-risk carriers not identified during routine care. “Our first goal was to deliver actionable health data back to the participants of the study and understand whether or not broad population screening of CDC Tier 1 genomic conditions was a practical tool to identify at-risk individuals,” explained Joseph Grzymski, Ph.D., the principal investigator of the Healthy Nevada Project®, a research professor at the Desert Research Institute (DRI), chief scientific officer for Renown Health and lead author of the study. “Now, two years into doing that, it is clear that the clinical guidelines for detecting risk in individuals are too narrow and miss too many at risk individuals.” Within the group of 26,906 Healthy Nevada Project® participants that Grzymski’s research team studied, 358 (1.33%) were carriers for CDC Tier 1 conditions. However, only 25% of those individuals met clinical guidelines for genetic screening. Additionally, more than 20% of the carriers already had a diagnosis of disease relevant to their underlying genetic condition. “We’re at a point now where it’s possible to do clinical-grade genetic screening at population-scale,” added James Lu, M.D. Ph.D., co-founder and chief scientific officer of Helix and senior co-author of the study. “What this study demonstrates is the potential impact of doing so. By making genetic screening available more broadly, we can help the millions of Americans who are unaware that they are living at increased risk for highly actionable, genetic conditions take action.” Most notably, the study found that of the 273 participants who were carriers of the CDC Tier 1 genetic conditions and had clinical record information, only 22 individuals showed any previous suspicion of their underlying genetic conditions. “For the first time, we are providing information at the individual level so study participants can make lifesaving changes to reduce their risk based on their genetics,” said Anthony Slonim, M.D., Dr.PH., FACHE, president and CEO of Renown Health and co-director of the Project® study. “We’re conducting research on the community level to develop leading-edge research on health determinants for entire neighborhoods, states and eventually, the country. Returning these results allows us to understand the prevalence of genetically programmed diseases and illnesses that we have here in Nevada and ensure we are providing the best prevention and care plans. For the individual, the return of results can be life changing.” According to the CDC, early detection and intervention of the Tier 1 genetic conditions could have a meaningful potential for clinical action ability and a positive impact on public health. The Healthy Nevada Project®, which launched in 2016, offers free genetic testing to every Nevadan, aged 18 and older, interested in learning more about their health and genetic profile. With more than 50,000 study participants enrolled in four years, the Healthy Nevada Project® has become the fastest-enrolling genetic study in the world. For more about the Healthy Nevada Project® please visit healthynv.org     Renown Institute for Health Innovation is a collaboration between Renown Health – a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California; and the Desert Research Institute – a recognized world leader in investigating the effects of natural and human induced environmental change and advancing technologies aimed at assessing a changing planet. Renown IHI research teams are focused on integrating personal healthcare and environmental data with socioeconomic determinants to help Nevada address some of its most complex environmental health problems; while simultaneously expanding the state’s access to leading-edge clinical trials and fostering new connections with biotechnology and pharmaceutical companies. Learn more at Healthynv.org. Helix is the leading population genomics company operating at the intersection of clinical care, research, and genomics. Its end-to-end platform enables health systems, life sciences companies, and payers to advance genomic research and accelerate the integration of genomic data into clinical care. Powered by one of the world's largest CLIA / CAP next-generation sequencing labs and its proprietary Exome+Ⓡ assay, Helix supports all aspects of population genomics including recruitment and engagement, clinically actionable disease screening, return of results, and basic and translational research. In response to the COVID-19 public health crisis, Helix has launched a sensitive and scalable end-to-end COVID-19 test system to meet the needs of health systems, employers, governments, and other organizations across the country. Learn more at www.helix.com.

Read More About Population Genetic Screening Show to Efficiently Identify Increased Risk for Inherited Disease